Pluristyx completed an investment round to expand inventory and commercial operations.
JUL 28, 2025
Pluristyx provides induced pluripotent stem cell (iPSC) products, gene-editing technologies, and development and GMP manufacturing services for clinical cell therapies
Pluristyx provides induced pluripotent stem cell (iPSC) products, gene-editing technologies, and development and GMP manufacturing services for clinical cell therapies. Its platform supports early product development through clinical-grade cell banking and commercialization, with a focus on genetically modified, allogeneic, off-the-shelf therapies.